ArticleJournal of hepatocellular carcinoma2026
A Single‑Center Retrospective Cohort Study: Impact of Glycemic Control on First‑Line TKI Plus PD‑1 Inhibitors versus TKI Alone in Intermediate‑to‑advanced Unresectable Hepatocellular Carcinoma(HCC) with Type 2 Diabetes Mellitus (T2DM).
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Type 2 diabetes mellitus (T2DM) is an independent risk factor for hepatocellular carcinoma (HCC), and the number of HCC patients with comorbid T2DM is increasing. Although tyrosine kinase inhibitor (TKI) monotherapy or combination with programmed death‑1 (PD‑1) inhibitors has become the first‑line standard of care for advanced HCC, most relevant clinical trials excluded patients with poorly controlled glycemia. Consequently, direct comparisons of efficacy and safety between first‑line regimens specifically in T2DM‑combined HCC populations remain insufficiently explored, and the impact of glycemic control on treatment outcomes also remains unclear. Therefore, this study retrospectively compares first‑line TKI monotherapy versus combined regimens in this population, with a focus on the effect of glycemic control status on prognosis, and aims to construct a prognostic nomogram integrating clinical and metabolic indicators to support individualized risk assessment. Methods: We retrospectively analyzed HCC patients with T2DM who received TKI monotherapy or TKI+PD-1 between January 2019 and January 2024. Overall survival (OS) and progression‑free survival (PFS) was analyzed using Cox regression (HR). Cancer‑specific death (with non‑cancer death as competing event) and PFS were evaluated using Fine‑Gray competing risk models (sHR). A prognostic nomogram incorporating independent predictors was developed and internally validated. Results: A total of 374 patients were enrolled (217 TKI+PD-1, 157 TKI), with 135 per group after Propensity Score Matching (PSM) (1:1). Post-PSM, the TKI group showed significantly inferior median OS (mOS: 20.7 months vs 26.8 months, HR=2.009, 95% CI 1.438-2.807, P<0.001) and PFS (mPFS: 11 months vs 16 months, HR=2.086, 95% CI 1.495-2.911; All P<0.001) compared to the TKI+PD-1 group. In the TKI cohort, poor glycemic control was associated with significantly worse OS (HR=2.125, 95% CI 1.215-3.714, P<0.001) and PFS (HR=2.210, 95% CI 1.292-3.781, P<0.001), but this association was not observed in the TKI+PD-1 cohort. The prognostic nomogram (corrected C index = 0.652) showed acceptable calibration and provided modest stratification patients into three risk groups (median OS: 19.3, 16.5 and 13.8 months, log rank P<0.001). Grade 1-2 diarrhea was lower in the TKI+PD-1 group (16.6% vs 26.8%, Conclusion: In HCC patients with T2DM, TKI+PD-1 offers superior OS and PFS compared to TKI alone. Glycemic control significantly impacts prognosis in patients receiving TKI monotherapy but its independent effect is diminished in those on combination immunotherapy. The proposed nomogram provides an individualized prognostic tool for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.